Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Jaguar Health

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Jaguar Health's Return On Capital Employed Insights

Jaguar Health's Return On Capital Employed Insights

Jaguar Health (NASDAQ:JAGX) brought in sales totaling $2.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 26.86%, resulting in a loss of $18.16 million.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Here's Why Jaguar Health Shares Are Rising

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer in the Mid

Here's Why Jaguar Health Shares Are Popping Off

Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer in the Middle East.

Jaguar Health Earnings Perspective: Return On Capital Employed

Jaguar Health (NASDAQ:JAGX) brought in sales totaling $2.08 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 17.44%, resulting in a loss of $14.32 million.

Jaguar Health's Earnings: A Preview

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate that Jaguar Health will report an earnings per share (EPS) of $-0.09.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

Bristol Myers Squibb

US Food and Drug Administration

KalVista Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Macular Degeneration

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play